Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00003956
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
- Conditions
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00004089
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Advanced Cancer
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 30
- Registration Number
- NCT00003331
- Locations
- 🇺🇸
Kaplan Cancer Center, New York, New York, United States
Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
- Conditions
- First Posted Date
- 2004-09-09
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 1976
- Registration Number
- NCT00091312
- Locations
- 🇫🇷
Centre Hospitalier Universitaire Ambroise Pare - Boulogne, Boulogne Billancourt, France
🇪🇬National Cancer Institute - Cairo, Cairo, Egypt
🇵🇹Instituto Portugues de Oncologia Centro do Porto, S. A., Porto, Portugal
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
- Conditions
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00003172
- Locations
- 🇺🇸
CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States
🇺🇸University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States
Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus
- Conditions
- First Posted Date
- 2004-09-03
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- European Institute of Oncology
- Target Recruit Count
- 240
- Registration Number
- NCT00002897
- Locations
- 🇮🇹
University of Padua, Padua, Italy
Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer
- Conditions
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 336
- Registration Number
- NCT00002793
- Locations
- 🇩🇪
Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
- Conditions
- Interventions
- First Posted Date
- 2004-09-01
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 68
- Registration Number
- NCT00002735
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Brooklyn, Brooklyn, New York, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States
S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed
- Conditions
- Interventions
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1135
- Registration Number
- NCT00002593
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸CentraCare Clinic, Saint Cloud, Minnesota, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
- Conditions
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 298
- Registration Number
- NCT00002631
- Locations
- 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CentraCare Clinic, Saint Cloud, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.